Michael Ehlers
About Michael Ehlers
Michael Ehlers is a prominent biotechnology executive, currently serving as the Founder, President, and Chief Executive Officer of Ascidian Therapeutics, and Co-Founder and Board Chair at multiple companies including Replicate Bioscience, Inc. and Aulos Bioscience. With a strong background in neuroscience and extensive leadership experience in the biotech industry, he focuses on developing synthetic RNA therapeutics and innovative therapies for various diseases.
Current Role at Ascidian Therapeutics
Michael Ehlers serves as the Founder, President, and Chief Executive Officer of Ascidian Therapeutics since 2023. The company is based in Boston, Massachusetts, and focuses on developing innovative therapies. Ehlers has been instrumental in leading the organization during its early stages, emphasizing the importance of synthetic RNA therapeutics and RNA exon editing.
Co-Founder and Board Chair at Replicate Bioscience
Ehlers co-founded Replicate Bioscience, Inc. in 2021 and currently holds the position of Board Chair. The company operates out of San Diego, California, and is engaged in advancing biotechnology solutions. His leadership role involves guiding the strategic direction of the organization and overseeing its research initiatives.
Professional Background and Experience
Ehlers has extensive experience in the biotechnology and pharmaceutical sectors. He has held significant positions at various organizations, including serving as Executive Vice President at Biogen and Senior Vice President at Pfizer. His roles have included leadership in neuroscience research and development, contributing to advancements in therapeutic approaches.
Educational Background
Michael Ehlers earned his MD and PhD in Medicine with a focus on Neuroscience from The Johns Hopkins University School of Medicine, completing his studies from 1991 to 1998. This foundational education has informed his career in neurobiology and therapeutic innovation.
Research and Development Focus
Ehlers leads research initiatives that target debilitating conditions across various medical fields, including ophthalmology, neurology, and rare diseases. His work emphasizes the development of designer synthetic RNA therapeutics and innovative technology platforms aimed at creating breakthrough therapies.